People

Chair

Samantha Singer

Samantha Singer is an Entrepreneur-in-Residence at Third Rock Ventures and President and CEO of Abata Therapeutics. She previously served as the Chief Operating Officer of the Broad Institute and, before that, was an executive at Biogen. Singer also served as an Independent Director on the Board for Rodin Therapeutics, until the company was acquired by Alkermes.

Steven C. Almo, Ph.D.

Steven C. Almo, Ph.D., is professor and chair of the Department of Biochemistry and professor of physiology and biophysics at Albert Einstein College of Medicine. He is an internationally recognized leader in the field of structural biology and immunology. His lab has been at the center of advancing high-throughput methods for expressing proteins, determining their structure and interrogating their function as well as developing innovative receptor-ligand de-orphaning platforms. Steve is also a co-founder and chair of the Scientific Advisory Board of Cue Biopharma.

Stephen Blacklow, MD, Ph.D.

Gustavus Adolphus Pfeiffer Professor and Chair of the Department of Biological Chemistry and Molecular Pharmacology at Harvard Medical School.

President and CEO | ex officio

Kenneth Fasman, Ph.D.

Kenneth Fasman, formerly senior vice president for research at The Jackson Laboratory, joined IPI as president and CEO in 2022. After earning his Ph.D. in biomedical engineering from the Johns Hopkins School of Medicine, he founded a bioscience laboratory systems company, BME Systems Inc., and went on to design and implement the original database for the groundbreaking Human Genome Project.

Fasman later pivoted to bioinformatics, drug discovery and research strategy, spending more than three decades with top pharmaceutical companies and nonprofit genomics institutes. Under his guidance, IPI takes on a three-fold mission to build resources, power discovery and enhance education within the protein science and biological research communities.

Jeffrey Flier, MD

Jeffrey Flier, MD, is the Higginson professor of physiology and medicine at Harvard Medical School and a leading authority in the molecular causes of obesity and diabetes. Dr. Flier served as the 21st dean of the Faculty of Medicine at Harvard University. He currently serves on the boards of several nonprofits, including Brandeis University, and companies, including Scholar Rock.

Maykin Ho, Ph.D.

Maykin Ho, Ph.D., retired as partner of Goldman Sachs & Co. after a 24 year-tenure, which included serving as advisory director of Global Healthcare Investment Banking and co-head of US Healthcare for Global Investment Research. She is a venture partner of Qiming Venture Partners and serves on the board of directors for Agios Pharmaceuticals, Parexel International and the Aaron Diamond AIDS Research Center.

Amir Nashat, Ph.D.

Amir Nashat, Ph.D. is a managing partner at Polaris Partners and focuses on investments in healthcare. He currently represents Polaris as the director of eight biotechnology startup companies and has served as the director of seven others. He has been named to the Forbes Midas List of “Top 100 Venture Capitalists.”

Mike O’Hara

Mike O’Hara is a partner at Deloitte and leads its New England life sciences audit practice. He has extensive experience working in the healthcare industry and serves many private and public life sciences companies. Mike has been involved in many IPOs; mergers and acquisitions engagements; financial forecasting projects; and value-added projects related to accounting and financial reporting. He has also assisted his clients through product launches and rapid growth phases, including advising on financial and operational infrastructure challenges. In addition to his role as board member for IPI, Mike is the treasurer of the Massachusetts Biotechnology Council and an adjunct professor at Boston College.

Co-Founder

Timothy A. Springer, Ph.D.

Timothy A. Springer, Ph.D. is the Latham Family Professor at Harvard Medical School and Boston Children’s Hospital. A world leader in structural biology and immunology, he is also a founder and private investor in ventures including LeukoSite, Scholar Rock, Morphic Therapeutic, Moderna Therapeutic, Editas Medicine, Selecta Biosciences and Ab Initio Biotherapeutics. His research and entrepreneurship have produced up to six FDA-approved drugs.

David Baker, Ph.D.

Professor of Biochemistry at the University of Washington; Investigator at the Howard Hughes Medical Institute.

Stephen Blacklow, MD, Ph.D.

Gustavus Adolphus Pfeiffer Professor and Chair of the Department of Biological Chemistry and Molecular Pharmacology at Harvard Medical School.

Shuqi Chen, Ph.D.

Founder, Former CEO and Former Chairman of the Board at IQuum, Inc.; Former Vice President of Research and Development of Point of Care at Roche Molecular System.

George Church, Ph.D.

Founding Faculty and Synthetic Biology Lead at the Wyss Institute; Robert Winthrop Professor of Genetics at Harvard Medical School; Professor of Health Sciences and Technology at Harvard and MIT.

Richard Cummings, Ph.D.

Director of the National Center for Functional Glycomics and Professor of Surgery at Beth Israel Deaconess Medical Center and Harvard Medical School.

Eric Fischer, Ph.D.

Assistant Professor of Biological Chemistry and Molecular Pharmacology at Harvard Medical School; Principal Investigator in the Department of Cancer Biology at Dana-Farber Cancer Institute.

K. Christopher Garcia, Ph.D.

Professor of Molecular and Cellular Physiology and of Structural Biology at Stanford University School of Medicine; Investigator at the Howard Hughes Medical Institute.

Michael Gladstone

Principal at Atlas Venture.

Stephen Harrison, Ph.D.

Giovanni Armenise-Harvard Professor of Basic Medical Sciences at Harvard Medical School and Boston Children’s Hospital; Investigator in the Howard Hughes Medical Institute.

John Hastewell, DPhil

Former Head of the Novartis Institutes for BioMedical Research Biologics Center (NBC).

Brian Kobilka, MD

Hélène Irwin Fagan Chair in Cardiology and Professor of Molecular and Cellular Physiology at Stanford University School of Medicine.

Nilesh Kumar, MBA, Ph.D.

Partner at Novo Ventures (US), Inc.

Judy Lieberman, MD, Ph.D.

Chair of the Program in Cellular and Molecular Medicine at Boston Children’s Hospital; Professor of Pediatrics at Harvard Medical School.

Harvey F. Lodish, Ph.D.

Professor of Biology and Biological Engineering at MIT; Founding Member of the Whitehead Institute for Biomedical Research; Co-Founder of Genzyme, Arris Pharmaceuticals, Millennium Pharmaceuticals and Rubius.

Deborah Marks, Ph.D.

Associate Professor of Systems Biology and Director of the Raymond and Beverly Sackler Laboratory at Harvard Medical School.

Werner Meier

Chief Scientific Officer at Revitope Oncology; Former Vice President of Biologics Drug Discovery at Biogen.

Timothy Mitchison, Ph.D.

Hasib Sabbagh Professor of Systems Biology at Harvard Medical School.

Saurabh Saha, MD, Ph.D.

Senior Vice President of R&D and Global Head of Translational Medicine at Bristol-Myers Squibb.

Arlene Sharpe, MD, Ph.D.

George Fabyan Professor of Comparative Pathology and Interim Co-Chair of Microbiology and Immunobiology at Harvard Medical School;
Co-Director of the Evergrande Center for Immunologic Diseases at Brigham and Women’s Hospital and Harvard Medical School.

Will Somers, Ph.D.

Vice President of Global Biotherapeutic Technologies at Pfizer.

Ulrich von Andrian, MD, Ph.D.

Mallinckrodt Professor of Immunopathology at Harvard Medical School.

Christopher Walsh, MD, Ph.D.

Chief of the Division of Genetics at Boston Children’s Hospital; Bullard Professor of Pediatrics and Neurology at Harvard Medical School.

Leonard I. Zon, MD

Grousbeck Professor of Pediatric Medicine at Harvard Medical School; Investigator at Howard Hughes Medical Institute; Director of the Stem Cell Program at Children’s Hospital Boston; Co-Founder of Scholar Rock.